Article
High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice.
INSERM U362, Institut Gustave Roussy, Villejuif, France, Service d'Anatomopathologie, Hôpital Cochin, Paris, France.
Blood (impact factor:
9.9).
01/1998;
90(11):4369-83.
pp.4369-83
Source: PubMed
-
Citations (0)
- Cited In (5)
-
Chapter: Molecular Mechanisms in Philadelphia Negative Myeloproliferative Neoplasia
03/2012; , ISBN: 978-953-51-0174-1 -
Article: Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.
[show abstract] [hide abstract]
ABSTRACT: Myelofibrosis is characterized by excessive deposits of extracellular matrix proteins, which occur as a marrow microenvironment reactive response to cytokines released from the clonal malignant myeloproliferation. The observation that mice exposed to high systemic levels of thrombopoietin (TPO) invariably developing myelofibrosis has allowed demonstration of the crucial role of transforming growth factor (TGF)-beta1 released by hematopoietic cells in the onset of myelofibrosis. The purpose of this study was to investigate whether TGF-beta1 inhibition could directly inhibit fibrosis development in a curative approach of this mice model. An adenovirus encoding for TGF-beta1 soluble receptor (TGF-beta-RII-Fc) was injected either shortly after transplantation (preventive) or 30 days post-transplantation (curative). Mice were transplanted with syngenic bone marrow cells transduced with a retrovirus encoding for murine TPO. All mice developed a myeloproliferative syndrome. TGF-beta-RII-Fc was detected in the blood of all treated mice, leading to a dramatic decrease in TGF-beta1 level. Histological analysis show that the two approaches (curative or preventive) were successful enough to inhibit bone marrow and spleen fibrosis development in this model. However, lethality of TPO overexpression was not decreased after treatment, indicating that in this mice model, myeloproliferation rather than fibrosis was probably responsible for the lethality induced by the disorder.Experimental Hematology 02/2007; 35(1):64-74. · 2.90 Impact Factor -
Article: GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1.
[show abstract] [hide abstract]
ABSTRACT: The DNA-binding hemopoietic zinc finger transcription factor GATA1 promotes terminal megakaryocyte differentiation and restrains abnormal immature megakaryocyte expansion. How GATA1 coordinates these fundamental processes is unclear. Previous studies of synthetic and naturally occurring mutant GATA1 molecules demonstrate that DNA-binding and interaction with the essential GATA1 cofactor FOG-1 (via the N-terminal finger) are required for gene expression in terminally differentiating megakaryocytes and for platelet production. Moreover, acquired mutations deleting the N-terminal 84 amino acids are specifically detected in megakaryocytic leukemia in human Down syndrome patients. In this study, we have systematically dissected GATA1 domains required for platelet release and control of megakaryocyte growth by ectopically expressing modified GATA1 molecules in primary GATA1-deficient fetal megakaryocyte progenitors. In addition to DNA binding, distinct N-terminal regions, including residues in the first 84 amino acids, promote platelet release and restrict megakaryocyte growth. In contrast, abrogation of GATA1-FOG-1 interaction leads to loss of differentiation, but growth of blocked immature megakaryocytes is controlled. Thus, distinct GATA1 domains regulate terminal megakaryocyte gene expression leading to platelet release and restrain megakaryocyte growth, and these processes can be uncoupled.Molecular and Cellular Biology 11/2005; 25(19):8592-606. · 5.53 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
10 months
4 months posttransplant
absolute numbers
bone marrow cells
colony-forming unit-erythroid numbers
giant platelets
granulocyte macrophage colony-forming cells
high-dose exposure
human idiopathic myelofibrosis
irregular granule distribution
lethal myeloproliferative disorder evolving
lethally irradiated mice
megakaryocyte colony-forming cell
mice results
murine TPO cDNA
red blood cell numbers
striking features
Total numbers
transduced hematopoietic cells
white blood cell